Rothschild & CO Asset Management Us Inc. Tcr2 Therapeutics Inc. Transaction History

Rothschild & CO Asset Management Us Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$4.58 - $8.34 $1.6 Million - $2.91 Million	-348,395 Closed	0 $0
Q3 2021 Nov 09, 2021	SELL	$8.44 - $18.35 $2.89 Million - $6.27 Million	-341,879 Reduced 49.53%	348,395 $2.97 Million
Q2 2021 Aug 16, 2021	BUY	$16.41 - $24.71 $2.16 Million - $3.25 Million	131,563 Added 23.55%	690,274 $11.3 Million
Q1 2021 May 14, 2021	SELL	$20.38 - $34.07 $2.66 Million - $4.44 Million	-130,338 Reduced 18.92%	558,711 $12.3 Million
Q4 2020 Feb 08, 2021	BUY	$19.0 - $32.63 $13.1 Million - $22.5 Million	689,049 New	689,049 $21.3 Million

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Rothschild & CO Asset Management Us Inc., based on Form 13F filings with the SEC.

Stay updated on Rothschild & CO Asset Management Us Inc. with notifications on news.